Granules India Ltd, a growing pharmaceutical manufacturing company, announced the financial results for its second quarter ended 30th September, 2017. The company's standalone sales during the quarter were INR 374 crore. In this quarter, the company recorded EBITDA and PAT of INR 84 crore and INR 36 crore, respectively. The company's Board of Directors has approved second interim dividend of 25 paise per share of face value of INR 1 each.

 

"We are pleased to report a moderate top-line growth for the current quarter compared with same quarter of the previous financial year. This comes at the backdrop of increased sales from formulation business and higher revenue generated from the North American market. As our emerging business is taking shape to drive future business growth, our core business continues to deliver sustainable revenues. During the quarter, we raised INR 300 crore through Qualified Institutional Placements (QIP). This not only validates the trust of our shareholders in the future prospects of the company but also helped us to fund our expansion plans," said Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India.